Алмазные фотоприемники ультрафиолетового диапазона

Изготовлены и исследованы планарные алмазные «солнечно-слепые» фотоприемники УФ-диапазона. Приведено теоретическое обоснование принципов работы и экспериментальные параметры фотоприемников в фоторезистивном и фотодиодном режимах

Study characteristics of studies included in meta-analysis (n = 16): regimens, population size, timepoint of analysis and virological outcome data are enlisted.

<p>INI-containing treatment arm is underlined.</p><p>ART = antiretroviral treatment; INI = integrase inhibitor; CTR = control arm; VL<50 = viral load or HIV RNA <50 copies/ml; RAL = raltegravir; EFV = efavirenz; EVG = elvitegravir; COBI = cobicistat; DTG = dolutegravir; ATV = atazanavir; DRV = darunavir; TDF/FTC = tenofovir/emtricitabine; ABC/3TC = abacavir/lamivudine; LPV = lopinavir; r = ritonavir; (N)NRTI = (non-)nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; BR = background regimen; T20 = enfurvirtide.</p

Overview of studies in systematic review, grouped according to study-design and indication: regimens, population size, treatment duration and summary of main outcome data and conclusions.

<p>GRADE level of evidence per category is added. INI-containing treatment arms are underlined.</p><p>(c)ART = (combination) antiretroviral treatment; INI = integrase inhibitor; CTR = control arm; (w) = weeks; VL<50 = viral load or HIV RNA <50 copies/ml; N = not applicable; RAL = raltegravir; EFV = efavirenz; EVG = elvitegravir; COBI = cobicistat; DTG = dolutegravir; ATV = atazanavir; DRV = darunavir; TDF/FTC = tenofovir/emtricitabine; ABC/3TC = abacavir/lamivudine; LPV = lopinavir; r = ritonavir; (N)NRTI = (non-)nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; BR = background regimen; T20 = enfurvirtide; NVP = nevirapin; HIBC = hyperimmune bovine colostrum.</p

Quality assessment of the selected studies in systematic review.

<p>Summary of the proportion of studies that fulfilled each quality assessment criterion. When no clear answer could be obtained for a specific criterion, it was classified as “unclear”. ART = Antiretroviral Treatment.</p

Prisma 2009 Flow diagram literature search and study selection.

<p>PRISMA diagram showing the different steps of systematic review, starting from literature search to study selection and exclusion. At each step, the reasons for exclusion are indicated.</p

Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase-1

four days and after 2, 4 and 6 passages the relative presence of both viruses in the culture was determined by sequencing. Shown are two representative experiments. The variability in each independent experiment is indicated by ± standard error of the mean (SEM). A: Pat A (E40F, M41L, K43E, M184V, L210W, T215Y and K219T) versus Pat A-WT43 (E40F, M41L, M184V, L210W, T215Y and K219T). B: wild type versus wild type+K43E. C: M41L+T215Y versus M41L+T215Y+K43E. D: M41L+T215Y+E40F versus M41L+T215Y+E40F+K43E.<p><b>Copyright information:</b></p><p>Taken from "Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase"</p><p>http://www.retrovirology.com/content/5/1/20</p><p>Retrovirology 2008;5():20-20.</p><p>Published online 13 Feb 2008</p><p>PMCID:PMC2276231.</p><p></p

Kaplan-Meier plot of time to virologic failure (VL>1000 cp/mL) and of time to detectable viremia (≥50 cp/mL).

<p>Kaplan-Meier plot of time to virologic failure (VL>1000 cp/mL) and of time to detectable viremia (≥50 cp/mL).</p

Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase-0

four days and after 2, 4 and 6 passages the relative presence of both viruses in the culture was determined by sequencing. Shown are two representative experiments. The variability in each independent experiment is indicated by ± standard error of the mean (SEM). A: M41L+T215Y versus M41L+T215Y+E40F B: Pat A (E40F, M41L, K43E, M184V, L210W, T215Y and K219T) versus Pat A-WT40 (M41L, K43E, M184V, L210W, T215Y and K219T).<p><b>Copyright information:</b></p><p>Taken from "Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase"</p><p>http://www.retrovirology.com/content/5/1/20</p><p>Retrovirology 2008;5():20-20.</p><p>Published online 13 Feb 2008</p><p>PMCID:PMC2276231.</p><p></p

Logistic Regression Analysis of correlates of detectable viremia>50 copies/mL at T0, multivariable analysis.

<p>Logistic Regression Analysis of correlates of detectable viremia>50 copies/mL at T0, multivariable analysis.</p

Levels of immune activation markers at T0.

<p>Lines indicate mean values. No significant difference in levels of soluble CD14 among the groups (p 0.489). There is a trend towards higher levels of CXCL9 in patients with low-level viremia and viral blips than in patients with continuously suppressed viremia (p 0.098).</p